The field of cardiac safety employs clinical, statistical, and regulatory sciences during the preclinical and clinical development program of a noncardiac drug to prospectively exclude unacceptable cardiac risk before the drug receives marketing approval. Since December 2012 can be said to mark the 15th Anniversary of the regulatory science of cardiac safety J. Rick TurnerQuintiles. Snehal Kothari, Christopher H. Cabell, Dilip Karnad. & Dhiraj Narula of Cardiac Safety Services at Quintiles, reflects upon the field’s history, review current state-of- the-science research, and consider directions in which the field may move in the five or so years.